अApnaFunda
Menu

AMRUTANJAN HEALTH CARE LIMITED (AMRUTANJAN)

Health Technology · Pharmaceuticals: Other · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.71 / 100
Profitability 90Growth 24Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.48 / 100
Price 63Earnings 43FII/DII 38
Compare withCIPLAAUROBINDO PHARMALUPIN

Share price

Closing priceAdjusted for splits and bonus issues.

₹519.85 latest close · −3.4% over the last 90 sessions

₹500₹520₹540Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹500₹520₹540Jul 3Sep 4Nov 9

₹519.85 month-end · −23.7% over 12 months

₹500₹600Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹500₹600Nov '25May '26Nov '26

₹519.85 month-end · −13.7% over 3 years

₹500₹600₹700₹800Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹500₹600₹700₹800Nov '23May '25Nov '26

₹519.85 month-end · +70.3% since Jan '19

₹400₹600₹800₹1,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹400₹600₹800₹1,000Jan '19Dec '22Nov '26

52-week range ₹476.50 to ₹744.00 · 1-year volatility 27.9%

Was the rally earned?

-24%share price, 1 yearMultiple-driven

Mostly the multiple.

  • Most of the fall came from investors paying a lower multiple (P/E 96.6x to 73.7x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: −24 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−24 ptsP/E changeShare price: −24%−24%Share priceP/E change: −24 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−24P/EShare price: −24%−24%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change-24 ptsThe P/E fell from 96.6x to 73.7x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
-14%share price, 3 yearsMultiple-driven

Mostly the multiple.

  • Most of the fall came from investors paying a lower multiple (P/E 85.4x to 73.7x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: −14 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−14 ptsP/E changeShare price: −14%−14%Share priceP/E change: −14 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−14P/EShare price: −14%−14%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change-14 ptsThe P/E fell from 85.4x to 73.7x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
-42%share price, 5 yearsMultiple-driven

Mostly the multiple.

  • Most of the fall came from investors paying a lower multiple (P/E 126.1x to 73.7x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: −41 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−41 ptsP/E changeShare price: −41%−41%Share priceP/E change: −41 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−41P/EShare price: −41%−41%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change-41 ptsThe P/E fell from 126.1x to 73.7x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with CIPLA

How rough has the ride been?

Maximum drawdown-50.8%not yet recovered
1-year volatility27.9%annualised
Beta vs sector index0.593-year daily, correlation 0.29
Volume spikes5last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−50.8% 0%−20%−40%2020202220242026−50.8%
Largest drawdowns

-50.8% (2021-11 peak to 2026-10 low, not yet recovered)

-48.6% (2020-02 peak to 2020-03 low, recovered 2021-01)

-17.9% (2019-11 peak to 2019-12 low, recovered 2020-02)

Most recent volume spikes

2026-08-21: 15.4x the 50-day median, price +2.8% that day

2026-08-20: 36.6x the 50-day median, price +4.6% that day

2026-08-12: 18.3x the 50-day median, price -8.5% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

73.7xP/E todayWithin its usual range
Against its own history33rd percentile
CheapestMedian 87.2xDearest

Usual range 49.4x to 114.9x since 2019-01.

Against Health Technology73.7x vs 37.0x
This company
73.7x
Sector median
37.0x

99% above the Health Technology median.

16.7x55.4x94.1x132.8xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x55.4x94.1x132.8xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE90thflat vs a year ago
  • Revenue growth18th▼ 7 pts vs a year ago
  • EPS growth37th▼ 4 pts vs a year ago
  • Debt/equity ↓86thflat vs a year ago
  • Cash cycle ↓87thflat vs a year ago
  • P/E ↓20th▲ 8 pts vs a year ago
  • 12M momentum12th▼ 46 pts vs a year ago

Rank history

ROCE
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~36%annual earnings growth implied by the price

At a P/E of 113.9x, the price would imply about 35.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Earnings figures have not updated recently, so the company is left out of the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹519.85
P/E
73.7x
ROCE
31.0%
Market Cap
₹1502 cr
Revenue (TTM)
₹177 cr
P/S
8.5x
P/B
13.8x
ROE
18.7%
Debt / Equity
0.0x
Promoter Holding
46.5%
12M Momentum
-23.7%

52-week range

₹476.50₹744.00
16% of the way from its 52-week low to its high

Price risk

1Y volatility
27.9%
Beta vs sector
1-year daily
0.38

Balance sheet & cash

Debt service
no meaningful debt
Cash from profit, 3Y
operating cash flow ÷ net profit
1.17x
Share count, 1Y
unchanged

Are profits backed by cash?

5 of 6checks within range1 near a threshold
Other income reliance15%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 15.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion1.17xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.17x (cash from operations ₹56 cr, net profit ₹48 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history0 daysWithin range

Debtor days are below the median of the previous three fiscal years by 0 days (57 vs 57). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress3% of fixed assetsWithin range

Capital work-in-progress is 3% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days0 days / 2 yrsWithin range

Days payable changed by 0 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 5.2 pts; promoters trimmed 4.1 pts; FIIs added 1.7 pts.
  • The number of shareholders fell from 72,002 to 45,135 (-37%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters50.6%46.5%-4.1 pts
FIIs0.8%2.4%+1.7 pts
DIIs7.1%12.3%+5.2 pts
Public and others41.4%38.7%-2.7 pts

Number of shareholders

45,135shareholders-37% since Sep '23
45k54k63k72k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 72,002
Dec '23: 68,404
Mar '24: 62,664
Jun '24: 57,169
Sep '24: 54,536
Dec '24: 53,856
Mar '25: 51,674
Jun '25: 49,431
Sep '25: 47,954
Dec '25: 46,675
Mar '26: 45,805
Jun '26: 45,135
 45k54k63k72k Sep '23Sep '24Sep '25Jun '26
Sep '23: 72,002
Dec '23: 68,404
Mar '24: 62,664
Jun '24: 57,169
Sep '24: 54,536
Dec '24: 53,856
Mar '25: 51,674
Jun '25: 49,431
Sep '25: 47,954
Dec '25: 46,675
Mar '26: 45,805
Jun '26: 45,135

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−4.5%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like AMRUTANJAN HEALTH CARE LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −30% to +21% vs the market, against 0% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −4.4%, 80% range −15.6% to −1.1%), but the matches cluster in only 5 distinct 12-month windows.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%+60%+80%
CELLO · Oct 2025: −47.1% vs market
TCIEXP · Jun 2023: −47.0% vs market
WENDT · Jan 2025: −46.1% vs market
APCOTEXIND · Nov 2023: −45.5% vs market
MOLDTKPAC · Aug 2023: −44.2% vs market
ALKYLAMINE · Mar 2023: −43.4% vs market
NATHBIOGEN · Feb 2020: −38.2% vs market
MATRIMONY · Jun 2022: −34.9% vs market
GOCOLORS · Feb 2024: −34.6% vs market
INDIGOPNTS · Jun 2023: −34.4% vs market
SUMICHEM · Apr 2023: −32.6% vs market
CLEAN · Nov 2024: −31.5% vs market
GILLETTE · Jan 2021: −30.9% vs market
PGHL · Aug 2023: −27.3% vs market
ORIENTELEC · Jun 2022: −26.7% vs market
MOIL · Jul 2025: −22.2% vs market
ACUTAAS · Jul 2023: −20.7% vs market
GLAXO · Apr 2022: −19.9% vs market
3MINDIA · Sep 2020: −17.1% vs market
RELAXO · Mar 2022: −16.0% vs market
GARFIBRES · Jan 2023: −14.5% vs market
VSTIND · Jan 2024: −11.9% vs market
ATUL · Oct 2021: −11.6% vs market
CHEVIOT · Aug 2023: −11.1% vs market
VGUARD · Jun 2020: −4.5% vs market
ICRA · Jul 2020: −4.5% vs market
VINATIORGA · Oct 2021: −3.9% vs market
HONAUT · Nov 2021: −1.8% vs market
TIMKEN · Jun 2025: −0.6% vs market
ASTRAL · Sep 2025: −0.3% vs market
LAOPALA · Jan 2020: +0.1% vs market
ACCELYA · Oct 2021: +2.5% vs market
GRINDWELL · Dec 2022: +2.8% vs market
RHIM · Mar 2020: +7.1% vs market
ASTRAZEN · May 2022: +8.5% vs market
ABBOTINDIA · Aug 2022: +12.7% vs market
ZFCVINDIA · Jun 2025: +14.7% vs market
TTKPRESTIG · Nov 2020: +23.0% vs market
FINEORG · Apr 2021: +26.7% vs market
CRISIL · Nov 2022: +27.8% vs market
TRITURBINE · Jul 2021: +29.9% vs market
BASF · Jan 2020: +32.6% vs market
SIRCA · Dec 2020: +35.3% vs market
CDSL · Jul 2023: +37.8% vs market
CERA · Jun 2022: +54.4% vs market
INGERRAND · Jul 2021: +54.6% vs market
EMAMILTD · Mar 2020: +59.1% vs market
KAJARIACER · May 2020: +62.2% vs market
CAMS · Dec 2023: +62.8% vs market
KPITTECH · Apr 2020: +121.5% vs market
Similar setups −4.5%All companies −0.1%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−4.5%
All companies' median
−0.1%
Beat the market
40% vs 50%

50 past situations · 50 companies · 38 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CHEVIOT
Process Industries		 Aug 2023 —— +2%−9% −11%
VSTIND
Consumer Non-Durables		 Jan 2024 88x34% +22%−9% −12%
INDIGOPNTS
Process Industries		 Jun 2023 52x— +2%−16% −34%
CLEAN
Process Industries		 Nov 2024 54x29% −6%−22% −32%
VGUARD
Producer Manufacturing		 Jun 2020 39x26% −30%−32% −5%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
APCOTEXIND
Process Industries		 Nov 2023 73x— +8%−9% −46%
BASF
Process Industries		 Jan 2020 42x25% −27%−33% +33%
ALKYLAMINE
Process Industries		 Mar 2023 55x41% −25%−36% −43%
How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. Not used (unavailable for this company): operating margin and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to AMRUTANJAN HEALTH CARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

VST INDUSTRIESVSTIND
Consumer Non-Durables
71%similar
revenue growthEPS growth
MOLD-TEK PACKAGINGMOLDTKPAC
Producer Manufacturing
48%similar
revenue growthEPS growth
CLEAN SCIENCE AND TECHNOLOGYCLEAN
Process Industries
44%similar
revenue growthpromoter holding
STEELCASTSTEELCAS
Non-Energy Minerals
41%similar
ROCEpromoter holding
TATA ELXSITATAELXSI
Technology Services
40%similar
revenue growthEPS growth
PFIZERPFIZER
Health Technology
35%similar
revenue growthEPS growth
PROCTER AND GAMBLE HEALTHPGHL
Health Technology
30%similar
debt/equityvolatility
ACCENT MICROCELLACCENTMIC
Health Technology
21%similar
market capdebt/equity

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jan '21

  1. OctPriceFell 51% from the Nov 2021 peak to the Oct 2026 low.
  2. AugPriceVolume reached 36.6x its 50-day median on 2026-08-20; price +4.6% that day.
  3. MayPriceVolume reached 10.8x its 50-day median on 2026-05-05; price -7.0% that day.
  4. MarPriceVolume reached 7.0x its 50-day median on 2026-03-23; price +0.4% that day.
  5. DecPriceVolume reached 6.6x its 50-day median on 2025-12-16; price +0.7% that day.
  6. AprPriceVolume reached 15.5x its 50-day median on 2025-04-15; price +5.9% that day.
  7. JanPriceVolume reached 21.5x its 50-day median on 2025-01-13; price -2.7% that day.
  8. DecPromoterPromoter holding fell 4.1 pts to 46.5%.
Show 22 earlier events
  1. DecInstitutionsFII + DII holding rose 4.3 pts over 2 quarters to 12.9%.
  2. NovPriceVolume reached 6.4x its 50-day median on 2024-11-13; price +2.8% that day.
  3. SepPriceVolume reached 34.1x its 50-day median on 2024-09-26; price -3.3% that day.
  4. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  5. MayPriceVolume reached 15.1x its 50-day median on 2024-05-02; price +12.2% that day.
  6. FebPriceVolume reached 44.5x its 50-day median on 2024-02-12; price +7.8% that day.
  7. JulPriceVolume reached 15.7x its 50-day median on 2023-07-03; price -4.7% that day.
  8. JunPriceVolume reached 113.2x its 50-day median on 2023-06-30; price +10.5% that day.
  9. FebPriceVolume reached 7.9x its 50-day median on 2023-02-15; price -7.8% that day.
  10. AugPriceVolume reached 19.5x its 50-day median on 2022-08-16; price -9.7% that day.
  11. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  12. AprValuationP/E crossed above the 90th percentile of its own history to date (128.6x).
  13. AprPriceVolume reached 5.0x its 50-day median on 2022-04-06; price +6.9% that day.
  14. FebPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  15. FebPriceVolume reached 7.9x its 50-day median on 2022-02-24; price +0.7% that day.
  16. NovPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  17. OctPriceVolume reached 11.9x its 50-day median on 2021-10-13; price +6.5% that day.
  18. SepPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  19. SepPriceVolume reached 42.2x its 50-day median on 2021-09-21; price +9.9% that day.
  20. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  21. FebPriceVolume reached 30.2x its 50-day median on 2021-02-12; price +10.0% that day.
  22. JanPriceRegained the 2020-02 peak, 10 months after the low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1173.7x₹177 cr18.7%31.0%0.0x
2026-1070.4x₹177 cr18.7%31.0%0.0x
2026-0973.0x₹177 cr18.7%31.0%0.0x
2026-0872.2x₹177 cr18.7%31.0%0.0x
2026-0773.0x₹177 cr18.7%31.0%0.0x
2026-0677.7x₹177 cr18.7%31.0%0.0x
2026-0579.2x₹177 cr18.7%31.0%0.0x
2026-0481.0x₹177 cr18.7%31.0%0.0x
2026-0370.0x₹177 cr18.7%31.0%0.0x
2026-0284.6x₹177 cr18.7%31.0%0.0x
2026-0182.8x₹177 cr18.7%31.0%0.0x
2025-1294.8x₹177 cr18.7%31.0%0.0x
2025-1196.6x₹177 cr18.7%31.0%0.0x
2025-10102.7x₹177 cr18.7%31.0%0.0x
2025-09101.2x₹177 cr18.7%31.0%0.0x
2025-0898.2x₹177 cr18.7%31.0%0.0x
2025-0793.6x₹177 cr18.7%31.0%0.0x
2025-06102.1x₹177 cr18.7%31.0%0.0x
2025-05101.0x₹177 cr18.7%31.0%0.0x
2025-0498.5x₹177 cr18.7%31.0%0.0x
2025-0392.5x₹177 cr18.7%31.0%0.0x
2025-0282.0x₹177 cr18.7%31.0%0.0x
2025-0194.5x₹177 cr18.7%31.0%0.0x
2024-12102.5x₹177 cr18.7%31.0%0.0x
2024-11104.7x₹177 cr18.7%31.0%0.0x
2024-10107.8x₹177 cr18.7%31.0%0.0x
2024-09115.8x₹177 cr18.7%31.0%0.0x
2024-08116.2x₹177 cr18.7%31.0%0.0x
2024-07107.2x₹177 cr18.7%31.0%0.0x
2024-06106.3x₹177 cr18.7%31.0%0.0x
2024-0598.1x₹177 cr18.7%31.0%0.0x
2024-0499.1x₹177 cr18.7%31.0%0.0x
2024-0388.0x₹177 cr18.7%31.0%0.0x
2024-0290.7x₹177 cr18.7%31.0%0.0x
2024-0182.2x₹177 cr18.7%31.0%0.0x
2023-1285.0x₹177 cr18.7%31.0%0.0x
2023-1185.4x₹177 cr18.7%31.0%0.0x
2023-1084.6x₹177 cr18.7%31.0%0.0x
2023-0987.4x₹177 cr18.7%31.0%0.0x
2023-0887.2x₹177 cr18.7%31.0%0.0x
2023-0793.3x₹177 cr18.7%31.0%0.0x
2023-06104.7x₹177 cr18.7%31.0%0.0x
2023-0586.2x₹177 cr18.7%31.0%0.0x
2023-0485.7x₹177 cr18.7%31.0%0.0x
2023-0381.7x₹177 cr18.7%31.0%0.0x
2023-0286.4x₹177 cr18.7%31.0%0.0x
2023-01102.3x₹177 cr18.7%31.0%0.0x
2022-12100.8x₹177 cr18.7%31.0%0.0x
2022-11100.5x₹177 cr18.7%31.0%0.0x
2022-10103.9x₹177 cr18.7%31.0%0.0x
2022-09101.4x₹177 cr18.7%31.0%0.0x
2022-08107.7x₹177 cr18.7%31.0%0.0x
2022-07113.7x₹177 cr18.7%31.0%0.0x
2022-06111.9x₹177 cr18.7%31.0%0.0x
2022-05116.8x₹177 cr18.7%31.0%0.0x
2022-04128.6x₹177 cr18.7%31.0%0.0x
2022-03112.7x₹177 cr18.7%31.0%0.0x
2022-02118.5x₹177 cr18.7%31.0%0.0x
2022-01117.3x₹177 cr18.7%31.0%0.0x
2021-12132.8x₹177 cr18.7%31.0%0.0x
2021-11126.1x₹177 cr18.7%31.0%0.0x
2021-10129.4x₹177 cr18.7%31.0%0.0x
2021-09118.5x₹177 cr18.7%31.0%0.0x
2021-08101.7x₹177 cr18.7%31.0%0.0x
2021-0796.9x₹177 cr18.7%31.0%0.0x
2021-0699.4x₹177 cr18.7%31.0%0.0x
2021-05100.6x₹177 cr18.7%31.0%0.0x
2021-0490.3x₹177 cr18.7%31.0%0.0x
2021-0380.5x₹177 cr18.7%31.0%0.0x
2021-0277.4x₹177 cr18.7%31.0%0.0x
2021-0170.1x₹177 cr18.7%31.0%0.0x
2020-1271.2x₹177 cr18.7%31.0%0.0x
2020-1171.6x₹177 cr18.7%31.0%0.0x
2020-1059.4x₹177 cr18.7%31.0%0.0x
2020-0960.0x₹177 cr18.7%31.0%0.0x
2020-0863.6x₹177 cr18.7%31.0%0.0x
2020-0761.0x₹177 cr18.7%31.0%0.0x
2020-0651.2x₹177 cr18.7%31.0%0.0x
2020-0548.2x₹177 cr18.7%31.0%0.0x
2020-0455.4x₹177 cr18.7%31.0%0.0x
2020-0346.8x₹177 cr18.7%31.0%0.0x
2020-0265.5x₹177 cr18.7%31.0%0.0x
2020-0164.6x₹177 cr18.7%31.0%0.0x
2019-1262.5x₹177 cr18.7%31.0%0.0x
2019-1163.3x₹177 cr18.7%31.0%0.0x
2019-1060.8x₹177 cr18.7%31.0%0.0x
2019-0951.2x₹177 cr18.7%31.0%0.0x
2019-0842.7x₹177 cr18.7%31.0%0.0x
2019-0740.3x₹177 cr18.7%31.0%0.0x
2019-0642.6x₹177 cr18.7%31.0%0.0x
2019-0544.4x₹177 cr18.7%31.0%0.0x
2019-0443.6x₹177 cr18.7%31.0%0.0x
2019-0343.9x₹177 cr18.7%31.0%0.0x
2019-0241.7x₹177 cr18.7%31.0%0.0x
2019-0143.3x₹177 cr18.7%31.0%0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback